Wound Management reviews alternatives to return to OTCBB

NewsGuard 100/100 Score

Wound Management Technologies, Inc., (WNDM.QB | WNDM.PK) a leader in advanced wound care solutions, today commented on the shift in the Company's stock quotation coverage which recently transitioned from the OTCBB to the OTCQB under the symbol "WNDM."  The shift in coverage to the OTCQB was caused by an unexpected migration of the Company's market makers away from the OTCBB, and does not affect, nor is it a reflection upon, Wound Management's business, operations or growth prospects.  

The OTCQB is one of three tiers established by OTC Markets Group, Inc., which operates one of the world's largest electronic interdealer quotation systems for broker-dealers to trade securities not listed on a national exchange. The OTCQB designation is meant to identify companies that are reporting with the SEC or a U.S. banking regulator, making it easy for investors to identify companies that are current in their reporting obligations.

Scott Haire, Chief Executive Officer of Wound Management, stated, "We have been told by several of our market makers that there is no technical difference between an OTCBB trading security and a fully reporting issuer trading on the OTCQB.  We are reviewing our alternatives to returning to the OTCBB.  In the meantime, our common stock will be quoted on the OTCQB, which can be viewed at www.otcmarkets.com."

SOURCE Wound Management Technologies, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
ZIP7: A novel target for treating degenerative diseases associated with misfolded proteins